Donor and Recipient Matching in Facial Vascularized Composite Allotransplantation: A Closer Look at the Donor Pool.
Adolescent
Adult
Aged
Cytomegalovirus
/ isolation & purification
Cytomegalovirus Infections
/ blood
Donor Selection
/ standards
Female
Hepacivirus
/ isolation & purification
Hepatitis C
/ blood
Humans
Male
Middle Aged
Retrospective Studies
Time Factors
Vascularized Composite Allotransplantation
/ standards
Waiting Lists
Young Adult
Journal
Plastic and reconstructive surgery
ISSN: 1529-4242
Titre abrégé: Plast Reconstr Surg
Pays: United States
ID NLM: 1306050
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
entrez:
28
6
2021
pubmed:
29
6
2021
medline:
18
9
2021
Statut:
ppublish
Résumé
Identifying a donor for facial vascularized composite allotransplant recipients can be a lengthy, emotionally challenging process. Little is known about the relative distribution of key donor characteristics among potential donors. Data on actual wait times of patients are limited, making it difficult to estimate wait times for future recipients. The authors retrospectively reviewed charts of nine facial vascularized composite allotransplant patients and provide data on transplant wait times and patient characteristics. In addition, they analyzed the United Network for Organ Sharing database of dead organ donors. After excluding donors with high-risk characteristics (e.g., active cancer or risk factors for blood-borne disease transmission), the authors calculated the distribution of relevant donor-recipient matching criteria (i.e., ethnicity, body mass index, age, ABO blood group, cytomegalovirus, Epstein-Barr virus, hepatitis C virus) among 65,201 potential donors. The median wait time for a transplant was 4 months (range, 1 day to 17 months). The large majority of United Network for Organ Sharing-recorded deaths from disease were white (63 percent) and male (58 percent). Female donors of black, Hispanic, or Asian descent are underrepresented, with 7, 5, and 1 percent of all recorded deaths from disease, respectively. Potential donors show cytomegalovirus and Epstein-Barr virus seropositivity of 65 and 95 percent, respectively. The number of annual hepatitis C-positive donors increased over time. Actual facial vascularized composite allotransplant wait times vary considerably. Although most patients experience acceptable wait times, some with underrepresented characteristics exceed acceptable levels. Cytomegalovirus-seropositive donors present a large portion of the donor pool, and exclusion for seronegative patients may increase wait time. Hepatitis C-seropositive donors may constitute a donor pool for underrepresented patient groups in the future.
Sections du résumé
BACKGROUND
BACKGROUND
Identifying a donor for facial vascularized composite allotransplant recipients can be a lengthy, emotionally challenging process. Little is known about the relative distribution of key donor characteristics among potential donors. Data on actual wait times of patients are limited, making it difficult to estimate wait times for future recipients.
METHODS
METHODS
The authors retrospectively reviewed charts of nine facial vascularized composite allotransplant patients and provide data on transplant wait times and patient characteristics. In addition, they analyzed the United Network for Organ Sharing database of dead organ donors. After excluding donors with high-risk characteristics (e.g., active cancer or risk factors for blood-borne disease transmission), the authors calculated the distribution of relevant donor-recipient matching criteria (i.e., ethnicity, body mass index, age, ABO blood group, cytomegalovirus, Epstein-Barr virus, hepatitis C virus) among 65,201 potential donors.
RESULTS
RESULTS
The median wait time for a transplant was 4 months (range, 1 day to 17 months). The large majority of United Network for Organ Sharing-recorded deaths from disease were white (63 percent) and male (58 percent). Female donors of black, Hispanic, or Asian descent are underrepresented, with 7, 5, and 1 percent of all recorded deaths from disease, respectively. Potential donors show cytomegalovirus and Epstein-Barr virus seropositivity of 65 and 95 percent, respectively. The number of annual hepatitis C-positive donors increased over time.
CONCLUSIONS
CONCLUSIONS
Actual facial vascularized composite allotransplant wait times vary considerably. Although most patients experience acceptable wait times, some with underrepresented characteristics exceed acceptable levels. Cytomegalovirus-seropositive donors present a large portion of the donor pool, and exclusion for seronegative patients may increase wait time. Hepatitis C-seropositive donors may constitute a donor pool for underrepresented patient groups in the future.
Identifiants
pubmed: 34181616
doi: 10.1097/PRS.0000000000008094
pii: 00006534-202107000-00031
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
194-202Informations de copyright
Copyright © 2021 by the American Society of Plastic Surgeons.
Références
Kauke M, Safi A-F, Zhegibe A, et al. Mucosa and rejection in facial vascularized composite allotransplantation: A systematic review. Transplantation. 2020;104:2616–2624.
Pomahac B, Pribaz J, Eriksson E, et al. Three patients with full facial transplantation. N Engl J Med. 2012;366:715–722.
Kauke M, Tchiloemba B, Haug V, Kollar B, Safi AF, Pomahac B. Partial loss of nasal tissue in a facial vascularized composite allograft patient. Plast Reconstr Surg Glob Open. 2020;8:e3038.
Fischer S, Lian CG, Kueckelhaus M, et al. Acute rejection in vascularized composite allotransplantation. Curr Opin Organ Transplant. 2014;19:531–544.
Chandraker A, Arscott R, Murphy GF, et al. The management of antibody-mediated rejection in the first presensitized recipient of a full-face allotransplant. Am J Transplant. 2014;14:1446–1452.
Huang A, Bueno EM, Pomahac B. A single center’s experience with donation of facial allografts for transplantation. Vascularized Compos Allotransplant. 2015;2:80–87.
Gordon CR, Avery RK, Abouhassan W, Siemionow M. Cytomegalovirus and other infectious issues related to face transplantation: Specific considerations, lessons learned, and future recommendations. Plast Reconstr Surg. 2011;127:1515–1523.
Siemionow MZ, Gordon CR. Institutional review board-based recommendations for medical institutions pursuing protocol approval for facial transplantation. Plast Reconstr Surg. 2010;126:1232–1239.
Levitsky J, Formica RN, Bloom RD, et al. The American Society of Transplantation Consensus Conference on the use of hepatitis C viremic donors in solid organ transplantation. Am J Transplant. 2017;17:2790–2802.
Lin MV, Sise ME, Pavlakis M, et al. Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection. PLoS One. 2016;11:e0158431.
Israni AK, Zaun D, Hadley N, et al. OPTN/SRTR 2018 annual data report: Deceased organ donation. Am J Transplant. 2020;20Suppl509–541.
Mendenhall SD, Ginnetti MT, Sawyer JD, et al. Prevalence and distribution of potential vascularized composite allotransplant donors, implications for optimizing the donor-recipient match. Plast Reconstr Surg Glob Open. 2018;6:e1833.
Erdbruegger U, Scheffner I, Mengel M, et al. Impact of CMV infection on acute rejection and long-term renal allograft function: A systematic analysis in patients with protocol biopsies and indicated biopsies. Nephrol Dial Transplant. 2012;27:435–443.
Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis. 2001;184:1461–1464.
Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant. 2002;2:850–856.
Knoll BM, Hammond SP, Koo S, et al. Infections following facial composite tissue allotransplantation: Single center experience and review of the literature. Am J Transplant. 2013;13:770–779.
Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV. Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients. Nephrol Dial Transplant. 2012;27:2971–2979.
Özkan Ö, Özkan Ö, Ubur M, Hadimioğlu N, Cengiz M, Afşar İ. Face allotransplantation for various types of facial disfigurements: A series of five cases. Microsurgery. 2018;38:834–843.
Dao A, Cuffy M, Kaiser TE, et al. Use of HCV Ab+/NAT- donors in HCV naïve renal transplant recipients to expand the kidney donor pool. Clin Transplant. 2019;33:e13598.
Hilbrands LB. Latest developments in living kidney donation. Curr Opin Organ Transplant. 2020;25:74–79.
Sharma M, Iyer S, P K, et al. Indian subcontinent’s first bilateral supracondylar level upper limb transplantation. Indian J Plast Surg. 2019;52:285–295.
Aflaki P, Nelson C, Balas B, Pomahac B. Simulated central face transplantation: Age consideration in matching donors and recipients. J Plast Reconstr Aesthet Surg. 2010;63:e283–e285.
Summers DM, Pettigrew GJ. Kidney transplantation following uncontrolled donation after circulatory death. Curr Opin Organ Transplant. 2020;25:144–150.
De Carlis R, Di Sandro S, Lauterio A, et al. Successful donation after cardiac death liver transplants with prolonged warm ischemia time using normothermic regional perfusion. Liver Transpl. 2017;23:166–173.
Hong JC, Yersiz H, Kositamongkol P, et al. Liver transplantation using organ donation after cardiac death: A clinical predictive index for graft failure-free survival. Arch Surg. 2011;146:1017–1023.
Haug V, Kollar B, Tasigiorgos S, et al. Hypothermic ex situ perfusion of human limbs with acellular solution for 24 hours. Transplantation. 2020;104:e260–e270.
Kling CE, Perkins JD, Landis CS, Limaye AP, Sibulesky L. Utilization of organs from donors according to hepatitis C antibody and nucleic acid testing status: Time for change. Am J Transplant. 2017;17:2863–2868.
Reese PP, Abt PL, Blumberg EA, et al. Twelve-month outcomes after transplant of hepatitis C-infected kidneys into uninfected recipients: A single-group trial. Ann Intern Med. 2018;169:273–281.
Seem DL, Lee I, Umscheid CA, Kuehnert MJ; United States Public Health Service. PHS guideline for reducing human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission through organ transplantation. Public Health Rep. 2013;128:247–343.
Tsiouris A, Wilson L, Sekar RB, Mangi AA, Yun JJ. Heart transplant outcomes in recipients of Centers for Disease Control (CDC) high risk donors. J Card Surg. 2016;31:772–777.
Cotter TG, Paul S, Sandikçi B, et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: Outcomes following liver transplant of HCV-viremic donors. Hepatology. 2019;69:2381–2395.
Woolley AE, Singh SK, Goldberg HJ, et al. DONATE HCV Trial Team. Heart and lung transplants from HCV-infected donors to uninfected recipients. N Engl J Med. 2019;380:1606–1617.
Kapuriya M, Vaidya A, Rajkumar V. Successful HIV-positive, live renal donor transplant: A unique method of expanding the donor pool. Transplantation. 2020;104:e140–e141.
Boyarsky BJ, Hall EC, Singer AL, Montgomery RA, Gebo KA, Segev DL. Estimating the potential pool of HIV-infected deceased organ donors in the United States: Estimating the potential pool of HIV-infected deceased organ donors. Am J Transplant. 2011;11:1209–1217.